Sweden
# |
Name |
EBIT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
44.95%
|
Dec. 31, 2023 | USD 17.87 | 3.09% |
|
Sweden |
|
2 |
-7.12%
|
Dec. 31, 2023 | USD 0.84 | -0.17% |
|
Sweden |
|
3 |
-152.24%
|
Dec. 31, 2023 | USD 0.23 | 11.53% |
|
Sweden |
|
4 |
-355.30%
|
Dec. 31, 2023 | USD 0.71 | -2.02% |
|
Sweden |
|
5 |
-383.98%
|
Dec. 31, 2023 | USD 0.11 | 1.51% |
|
Sweden |
|
6 |
-393.45%
|
Aug. 31, 2024 | USD 0.22 | -6.29% |
|
Sweden |
|
7 |
-461.04%
|
Dec. 31, 2023 | USD 2.74 | 1.67% |
|
Sweden |
|
8 |
-540.88%
|
Dec. 31, 2023 | USD 2.91 | -2.20% |
|
Sweden |
|
9 |
-643.30%
|
Dec. 31, 2023 | USD 0.21 | 0.68% |
|
Sweden |
|
10 |
-675.99%
|
Dec. 31, 2023 | USD 0.39 | 2.53% |
|
Sweden |
|
11 |
-859.59%
|
Dec. 31, 2023 | USD 0.28 | -7.61% |
|
Sweden |
|
12 |
-2,942.11%
|
Dec. 31, 2023 | USD 0.80 | 0.68% |
|
Sweden |
|
13 |
-3,128.57%
|
Dec. 31, 2023 | USD 0.90 | 9.88% |
|
Sweden |
|
14 |
-5,140.22%
|
Dec. 31, 2023 | USD 0.20 | 1.12% |
|
Sweden |
|
15 |
-6,269.47%
|
Dec. 31, 2023 | USD 0.10 | 0.68% |
|
Sweden |
|
16 |
-70,111.32%
|
Dec. 31, 2023 | USD 1.17 | -3.73% |
|
Sweden |
|
17 |
-117,450.00%
|
Aug. 31, 2024 | USD 1.61 | 0.34% |
|
Sweden |
|
18 |
-530,066.67%
|
Dec. 31, 2023 | USD 0.45 | 23.08% |
|
Sweden |
The Clinical Trials company in Sweden with the highest EBIT Margin is BioArctic AB (publ) (Stockholm Stock Exchange: BIOA-B.ST) at 44.95%.
The Clinical Trials company in Sweden with the lowest EBIT Margin is OncoZenge AB (publ) (Stockholm Stock Exchange: ONCOZ.ST) at -530,066.67%.
The top 10 Clinical Trials companies in Sweden by EBIT Margin are BioArctic AB (publ), Corline Biomedical AB, Elicera Therapeutics AB (publ), Mendus AB (publ), Aptahem AB (publ), NextCell Pharma AB, BioInvent International AB (publ), Hansa Biopharma AB (publ), CombiGene AB (publ) and Pila Pharma AB (publ).
The bottom 10 Clinical Trials companies in Sweden by EBIT Margin are OncoZenge AB (publ), Diamyd Medical AB (publ), Lipum AB (publ), Kancera AB (publ), Isofol Medical AB (publ), IRLAB Therapeutics AB (publ), Prostatype Genomics AB (publ), Clinical Laserthermia Systems AB (publ), Pila Pharma AB (publ) and CombiGene AB (publ).